Vertex Pharmaceuticals Inc / Ma (VRTX) Files Form 4 Insider Selling : Ian F Smith Sells 202 Shares

Vertex Pharmaceuticals Inc / Ma (VRTX): Ian F Smith , EVP & CFO of Vertex Pharmaceuticals Inc / Ma sold 202 shares on May 16, 2016. The Insider selling transaction was reported by the company on May 18, 2016 to the Securities and Exchange Commission. The shares were sold at $82.06 per share for a total value of $16,576.12 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 13, 2016, Joshua S Boger (director) sold 5,130 shares at $86.31 per share price.On May 11, 2016, Paul M Silva (SVP & Corp Controller) sold 3,000 shares at $87.54 per share price.Also, On Feb 4, 2016, Ian F Smith (EVP & CFO) sold 12,084 shares at $91.32 per share price.On Feb 4, 2016, Amit Sachdev (EVP, Policy, Access & Value) sold 10,166 shares at $91.38 per share price.

Shares of Vertex Pharmaceuticals Incorporated (VRTX) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.7 points or -0.86% at $81.01 with 16,74,371 shares getting traded. Post opening the session at $80.89, the shares hit an intraday low of $80.25 and an intraday high of $82.29 and the price vacillated in this range throughout the day. The company has a market cap of $20,038 M and the number of outstanding shares has been calculated to be 24,73,49,860 shares. The 52-week high of Vertex Pharmaceuticals Incorporated is $143.45 and the 52-week low is $75.9.

Vertex Pharmaceuticals Incorporated Money Flow Index Chart

Company has been under the radar of several Street Analysts.Vertex Pharmaceuticals Incorporated is Reiterated by RBC Capital Mkts to Outperform while Lowering the Price Target of the company shares to $ 115 from a previous price target of $135 . The Rating was issued on Apr 28, 2016.Vertex Pharmaceuticals Incorporated is Reiterated by Barclays to Overweight while Lowering the Price Target of the company shares to $ 110 from a previous price target of $135 . The Rating was issued on Apr 28, 2016.Vertex Pharmaceuticals Incorporated is Downgraded by Goldman to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Apr 28, 2016.Vertex Pharmaceuticals Incorporated is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 108 from a previous price target of $140 . The Rating was issued on Apr 1, 2016.Vertex Pharmaceuticals Incorporated is Reiterated by RBC Capital Mkts to Outperform while Lowering the Price Target of the company shares to $ 135 from a previous price target of $145 . The Rating was issued on Mar 18, 2016.

Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertex’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Company’s product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Company’s product KALYDECO is available in the market.

Leave a Reply

Vertex Pharmaceuticals Incorporated - Is it time to Sell?

Top Brokerage Firms are advising their investors on Vertex Pharmaceuticals Incorporated. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.